JP2000509404A5 - - Google Patents

Download PDF

Info

Publication number
JP2000509404A5
JP2000509404A5 JP1997539526A JP53952697A JP2000509404A5 JP 2000509404 A5 JP2000509404 A5 JP 2000509404A5 JP 1997539526 A JP1997539526 A JP 1997539526A JP 53952697 A JP53952697 A JP 53952697A JP 2000509404 A5 JP2000509404 A5 JP 2000509404A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1997539526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000509404A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1997/002268 external-priority patent/WO1997041834A1/en
Publication of JP2000509404A publication Critical patent/JP2000509404A/ja
Publication of JP2000509404A5 publication Critical patent/JP2000509404A5/ja
Pending legal-status Critical Current

Links

JP9539526A 1996-05-08 1997-05-04 遺伝物質の導入システムとしてのカチオン性ヴィロソーム Pending JP2000509404A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96107282 1996-05-08
EP96107282.4 1996-05-08
PCT/EP1997/002268 WO1997041834A1 (en) 1996-05-08 1997-05-04 Cationic virosomes as transfer system for genetic material

Publications (2)

Publication Number Publication Date
JP2000509404A JP2000509404A (ja) 2000-07-25
JP2000509404A5 true JP2000509404A5 (enExample) 2005-02-10

Family

ID=8222763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9539526A Pending JP2000509404A (ja) 1996-05-08 1997-05-04 遺伝物質の導入システムとしてのカチオン性ヴィロソーム

Country Status (28)

Country Link
US (1) US6210708B1 (enExample)
EP (1) EP0902682A2 (enExample)
JP (1) JP2000509404A (enExample)
KR (1) KR100536983B1 (enExample)
CN (1) CN1271992C (enExample)
AR (1) AR007054A1 (enExample)
AU (1) AU710170B2 (enExample)
BG (1) BG102880A (enExample)
BR (1) BR9709224A (enExample)
CA (1) CA2253561A1 (enExample)
CO (1) CO4600638A1 (enExample)
CZ (1) CZ299809B6 (enExample)
EA (1) EA003130B1 (enExample)
GT (1) GT199700058A (enExample)
HR (1) HRP970234B1 (enExample)
HU (1) HUP9901790A3 (enExample)
ID (1) ID17934A (enExample)
NO (1) NO327726B1 (enExample)
NZ (1) NZ332666A (enExample)
OA (1) OA10916A (enExample)
PA (1) PA8429201A1 (enExample)
PE (1) PE65198A1 (enExample)
PL (1) PL199201B1 (enExample)
SK (1) SK152698A3 (enExample)
SV (1) SV1997000032A (enExample)
TN (1) TNSN97080A1 (enExample)
WO (1) WO1997041834A1 (enExample)
ZA (1) ZA973885B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
AU9224398A (en) * 1997-09-08 1999-03-29 Promega Corporation Method of (in vivo) transformation utilizing lipid vehicles
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
HUP0202809A2 (hu) * 1999-10-08 2002-12-28 Nika Health Products Limited Kationos DOSPER-viroszómák
DE50002682D1 (de) * 1999-12-17 2003-07-31 Schott Glas Induktiv aktivierbare zündkapsel für insassen-rückhaltesysteme und prüfschaltung für diese zündkapsel
WO2001052901A1 (en) * 2000-01-21 2001-07-26 Hisamitsu Pharmaceutical Co., Inc. Drugs for gene therapy
EP1409653A4 (en) * 2001-07-23 2006-05-03 Onyx Pharma Inc IN HUMAN TARGET CANCELLS SELECTIVELY REPLICATING VIRUS MUTANTS
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
WO2003038103A1 (en) * 2001-10-29 2003-05-08 Atso Raasmaja Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
AU2003288119B2 (en) * 2002-11-21 2009-08-20 Pevion Biotech Ltd. High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them
WO2005056752A2 (en) 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
US20070172520A1 (en) * 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
CA2921063C (en) 2006-09-15 2020-01-28 Ottawa Hospital Research Institute Oncolytic rhabdovirus
KR101242113B1 (ko) * 2010-10-22 2013-03-19 고마바이오텍(주) 유전자 전달용 양이온성 센다이 f/hn 바이로좀 복합체
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
EP2763696B1 (en) * 2011-10-07 2018-09-19 iSD Immunotech ApS Identification of the immunosuppressive domains in fusion proteins of enveloped rna viruses
US11241476B2 (en) 2016-09-27 2022-02-08 Camurus Ab Mixtures and formulations comprising an alkyl ammonium EDTA salt
CN109055432B (zh) * 2018-08-16 2020-10-13 南京科佰生物科技有限公司 慢病毒感染试剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
CA2086831C (en) * 1991-05-08 1999-03-16 Reinhard Gluck Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
AU3614493A (en) 1992-02-04 1993-09-01 Chiron Corporation Non-toxic lipid vaccine formulations
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
WO1995002698A1 (en) * 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
EP0762870B1 (en) * 1994-05-31 2002-09-11 INEX Pharmaceutical Corp. Virosome-mediated intracellular delivery of therapeutic agents
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2000501324A5 (enExample)
JP2000500055A5 (enExample)
JP2000502472A5 (enExample)
JP2000501825A5 (enExample)
JP2000501338A5 (enExample)
JP2000500874A5 (enExample)
JP2000502425A5 (enExample)
JP2000502485A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2000501744A5 (enExample)
JP2000501229A5 (enExample)
JP2000502316A5 (enExample)
JP2000500857A5 (enExample)
JP2000502714A5 (enExample)
JP2000501569A5 (enExample)
JP2000509404A5 (enExample)